Answers are grounded in this paper and cite their sources.
Cost-effective adjunctive therapy improves HFrEF management in China, suggesting inclusion in clinical guidelines.
QLQX capsules, as adjunctive therapy to standard treatment, represent a cost-effective strategy for managing HFrEF in China, supporting their inclusion in clinical guidelines and reimbursement policies. Real-world studies are needed to validate these results further.
No takes yet. Share an insight, caveat, or question.
Lou et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: